Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the NAL Pharmaceuticals Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of NAL Pharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of NAL Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of NAL Pharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the NAL Pharmaceuticals Ltd.'s pipeline products Reasons to buy - Evaluate NAL Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of NAL Pharmaceuticals Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the NAL Pharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of NAL Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of NAL Pharmaceuticals Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of NAL Pharmaceuticals Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 NAL Pharmaceuticals Ltd. Snapshot 6 NAL Pharmaceuticals Ltd. Overview 6 Key Information 6 Key Facts 6 NAL Pharmaceuticals Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 NAL Pharmaceuticals Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 NAL Pharmaceuticals Ltd. - Pipeline Products Glance 12 NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products 13 Unknown Products/Combination Treatment Modalities 13 NAL Pharmaceuticals Ltd. - Drug Profiles 15 pegfilgrastim 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 diclofenac sodium 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 donepezil hydrochloride 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 donepezil hydrochloride Patch 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 formoterol fumarate patch 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 galantamine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 indomethacin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ketoprofen 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 levocetirizine dihydrochloride 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 montelukast sodium 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 NAL-3216 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NAL-3221 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NAL-3223 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 nicotine bitartrate 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 rizatriptan benzoate 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 sildenafil citrate 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 sufentanil 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 tadalafil 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 tulobuterol 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 NAL Pharmaceuticals Ltd. - Pipeline Analysis 34 NAL Pharmaceuticals Ltd. - Pipeline Products by Target 34 NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 35 NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 36 NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 37 NAL Pharmaceuticals Ltd. - Dormant Projects 38 NAL Pharmaceuticals Ltd. - Locations And Subsidiaries 39 Head Office 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables NAL Pharmaceuticals Ltd., Key Information 6 NAL Pharmaceuticals Ltd., Key Facts 6 NAL Pharmaceuticals Ltd. - Pipeline by Indication, 2014 9 NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014 10 NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014 11 NAL Pharmaceuticals Ltd. - Preclinical, 2014 12 NAL Pharmaceuticals Ltd. - Unknown, 2014 13 NAL Pharmaceuticals Ltd. - Pipeline by Target, 2014 34 NAL Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2014 35 NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2014 36 NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014 37 NAL Pharmaceuticals Ltd. - Dormant Developmental Projects,2014 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.